Ken-Ichi Hanada Selected Research

Ken-Ichi Hanada Research Topics

14	Neoplasms (Cancer) 10/2023 - 12/2004
4	Melanoma (Melanoma, Malignant) 01/2021 - 11/2010
2	Adenocarcinoma of Lung 01/2021 - 11/2016
2	Kidney Neoplasms (Kidney Cancer) 03/2008 - 01/2004
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Genomic Instability 11/2016
1	Neoplasm Metastasis (Metastasis) 11/2016
1	Hematologic Neoplasms (Hematological Malignancy) 03/2008

6	AntigensIBA 01/2023 - 01/2004
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
2	EpitopesIBA 01/2022 - 01/2019
2	Peptides (Polypeptides)IBA 01/2021 - 12/2004
2	VaccinesIBA 01/2021 - 12/2004
2	Biomarkers (Surrogate Marker)IBA 05/2014 - 11/2010
2	Interleukin-2 (IL2)IBA 11/2010 - 12/2004
1	Indicators and Reagents (Reagents)IBA 10/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Chimeric Antigen ReceptorsIBA 05/2017
1	CytokinesIBA 01/2015
1	VemurafenibIBA 01/2015
1	MucinsIBA 05/2014
1	Immunoglobulins (Immunoglobulin)IBA 05/2014
1	Member 9 Tumor Necrosis Factor Receptor SuperfamilyIBA 05/2014
1	InterferonsIBA 11/2010
1	Programmed Cell Death 1 ReceptorIBA 11/2010
1	Hepatitis B e AntigensIBA 03/2008
1	PerforinIBA 12/2004
1	Caspase 3 (Caspase-3)IBA 12/2004
1	LigandsIBA 12/2004
1	MethylcholanthreneIBA 12/2004

9	Therapeutics 01/2023 - 11/2010
6	Immunotherapy 01/2022 - 01/2015
3	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2023 - 11/2010
1	Drug Therapy (Chemotherapy) 11/2016
1	Stem Cell Transplantation 03/2008
1	Hematopoietic Stem Cell Transplantation 03/2008